| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marlene M Hsieh, George Lupas, Jennifer Rychlik, Suzan Dziennis, Beth A Habecker, Elaine J Lewi. ERK1/2 is a negative regulator of homeodomain protein Arix/Phox2a. Journal of neurochemistry. vol 94. issue 6. 2005-10-27. PMID:16156742. |
treatment of sympathetic neurons with the mek1 inhibitor, pd98059, results in an elevation of mrnas encoding noradrenergic proteins, dopamine beta-hydroxylase (dbh) and norepinephrine transporter (net), but not tyrosine hydroyxlase (th). |
2005-10-27 |
2023-08-12 |
Not clear |
| Meng-Yang Zhu, Wei-Ping Wang, Abiye H Iyo, Gregory A Ordway, Kwang-Soo Ki. Age-associated changes in mRNA levels of Phox2, norepinephrine transporter and dopamine beta-hydroxylase in the locus coeruleus and adrenal glands of rats. Journal of neurochemistry. vol 94. issue 3. 2005-09-19. PMID:16033425. |
age-related changes in the gene expression of the transcription factors, phox2a and 2b, and two marker proteins, norepinephrine transporter (net) and dopamine beta-hydroxylase (dbh), of noradrenergic neurons were characterized in the locus coeruleus (lc) and adrenal glands using in situ hybridization. |
2005-09-19 |
2023-08-12 |
rat |
| S Rossi, S Singer, E Shearman, H Sershen, A Lajth. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochemical research. vol 30. issue 4. 2005-08-24. PMID:16076024. |
in the hippocampal and cortical areas, the mechanisms of nicotine-induced dopamine increase seem to be similar, but the mechanisms seem to be different for noradrenergic and serotonergic systems, as shown by the fact that nicotine induces no change in norepinephrine and a decrease in serotonin in the hippocampus, while it induces an increase in both in the cortex. |
2005-08-24 |
2023-08-12 |
rat |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
medication with dopaminergic and noradrenergic activity seems to reduce adhd symptoms by blocking dopamine and norepinephrine reuptake. |
2005-07-29 |
2023-08-12 |
Not clear |
| Bertha K Madras, Gregory M Miller, Alan J Fischma. The dopamine transporter and attention-deficit/hyperactivity disorder. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15950014. |
thus, adhd medications targeting dat or net might disperse dopamine widely and consign dopamine storage and release to regulation by noradrenergic, as well as dopaminergic neurons. |
2005-07-29 |
2023-08-12 |
human |
| Maggie S Burhans, Catherine Dailey, Zachary Beard, Jason Wiesinger, Laura Murray-Kolb, Byron C Jones, John L Bear. Iron deficiency: differential effects on monoamine transporters. Nutritional neuroscience. vol 8. issue 1. 2005-07-22. PMID:15909765. |
in this study, we extend previous work on iron deficiency and dopamine (da) transporters to include an examination of central serotonin (5-ht) and noradrenergic (ne) transporters. |
2005-07-22 |
2023-08-12 |
rat |
| Eric C Dumont, John T William. Noradrenaline triggers GABAA inhibition of bed nucleus of the stria terminalis neurons projecting to the ventral tegmental area. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 24. issue 38. 2005-07-07. PMID:15385602. |
this mechanism might contribute to the withdrawal-induced inhibition of dopamine neurons and explain how noradrenergic drugs microinjected into the vlbnst reduce aversive aspects of opioid withdrawal. |
2005-07-07 |
2023-08-12 |
Not clear |
| Paola Devoto, Giovanna Flore, Pierluigi Saba, Mauro Fà, Gian Luigi Gess. Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. Journal of neurochemistry. vol 92. issue 2. 2005-05-26. PMID:15663484. |
our previous studies have suggested that dopamine and noradrenaline may be coreleased from noradrenergic nerve terminals in the cerebral cortex. |
2005-05-26 |
2023-08-12 |
rat |
| Paola Devoto, Giovanna Flore, Pierluigi Saba, Mauro Fà, Gian Luigi Gess. Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. Journal of neurochemistry. vol 92. issue 2. 2005-05-26. PMID:15663484. |
these results indicate that electrical stimulation-induced increase of dopamine is a nerve impulse exocytotic process and suggest that cortical dopamine and noradrenaline may be coreleased from noradrenergic terminals. |
2005-05-26 |
2023-08-12 |
rat |
| V Valentini, F Cacciapaglia, R Frau, G Di Chiar. Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation. Journal of neurochemistry. vol 93. issue 2. 2005-05-20. PMID:15816860. |
selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1a receptors and independence from noradrenergic innervation. |
2005-05-20 |
2023-08-12 |
Not clear |
| Dong-Youn Hwang, Michelle M Hwang, Han-Soo Kim, Kwang-Soo Ki. Genetically engineered dopamine beta-hydroxylase gene promoters with better PHOX2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner. Molecular therapy : the journal of the American Society of Gene Therapy. vol 11. issue 1. 2005-05-04. PMID:15585414. |
genetically engineered dopamine beta-hydroxylase gene promoters with better phox2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner. |
2005-05-04 |
2023-08-12 |
human |
| Ryan T Lalumiere, Linda T Nguyen, James L McGaug. Post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. The European journal of neuroscience. vol 20. issue 10. 2005-03-01. PMID:15548223. |
post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. |
2005-03-01 |
2023-08-12 |
rat |
| Karen S Rommelfanger, David Weinshenker, Gary W Mille. Reduced MPTP toxicity in noradrenaline transporter knockout mice. Journal of neurochemistry. vol 91. issue 5. 2005-02-10. PMID:15569255. |
neurotoxin ablation of the lc noradrenergic neurons has been shown to exacerbate the dopaminergic toxicity of mptp, suggesting that the noradrenergic system protects dopamine neurons. |
2005-02-10 |
2023-08-12 |
mouse |
| Benjamin Boutrel, George F Koo. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep. vol 27. issue 6. 2005-02-08. PMID:15532213. |
the role of several neurotransmitter or neuromodulator systems, including noradrenergic, serotonergic, cholinergic, adenosinergic, and histaminergic systems and, more recently, the hypocretin/orexin and dopamine systems, has been clearly established. |
2005-02-08 |
2023-08-12 |
Not clear |
| Natsuki Matsushita, Kenta Kobayashi, Jun-ichi Miyazaki, Kazuto Kobayash. Fate of transient catecholaminergic cell types revealed by site-specific recombination in transgenic mice. Journal of neuroscience research. vol 78. issue 1. 2005-02-07. PMID:15372500. |
we developed a cre-loxp-mediated recombination system under the control of the dopamine beta-hydroxylase (dbh) promoter, which drives gene expression in typical noradrenergic and adrenergic cell groups as well as in transient catecholaminergic cell types. |
2005-02-07 |
2023-08-12 |
mouse |
| Bret A Morrow, Tony P George, Robert H Rot. Noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry. Brain research. vol 1027. issue 1-2. 2005-02-07. PMID:15494168. |
noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry. |
2005-02-07 |
2023-08-12 |
rat |
| Tomas Palomo, R M Kostrzewa, R J Beninger, T Arche. Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. Neurotoxicity research. vol 6. issue 5. 2005-01-26. PMID:15545018. |
the successful intervention into alcohol dependence and craving brought about by baclofen in both human and animal studies elucidates glutamatergic mechanisms in alcoholism whereas the role of the dopamine transporter, in conjunction with both the noradrenergic and serotonergic transporters, are implicated in cocaine dependence and craving. |
2005-01-26 |
2023-08-12 |
human |
| K Magyar, M Pálfi, T Tábi, H Kalász, B Szende, E Szök. Pharmacological aspects of (-)-deprenyl. Current medicinal chemistry. vol 11. issue 15. 2004-12-23. PMID:15279565. |
beside its dopamine potentiating effect, it renders protection against a number of dopaminergic, cholinergic and noradrenergic neurotoxins with a complex mechanism of action. |
2004-12-23 |
2023-08-12 |
Not clear |
| Bob Oranje, René S Kahn, Chantal Kemner, Marinus N Verbate. Modulating sensorimotor gating in healthy volunteers: the effects of desipramine and haloperidol. Psychiatry research. vol 127. issue 3. 2004-12-14. PMID:15296819. |
the site for this interaction is most likely located in the prefrontal cortex, since evidence is accumulating that extracellular dopamine concentration is regulated by noradrenergic terminals, particularly in the frontal areas of the brain. |
2004-12-14 |
2023-08-12 |
human |
| Paola Devoto, Giovanna Flore, Luigi Pira, Giorgio Longu, Gian Luigi Gess. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033381. |
mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. |
2004-11-24 |
2023-08-12 |
Not clear |